AbbVie Inc (ABBV)

61.99
0.71 1.16
NYSE : Health Care
Prev Close 61.28
Open 61.39
Day Low/High 61.05 / 62.41
52 Wk Low/High 51.60 / 68.12
Volume 7.30M
Avg Volume 8.16M
Exchange NYSE
Shares Outstanding 1.63B
Market Cap 99.59B
EPS 3.10
P/E Ratio 16.56
Div & Yield 2.56 (4.20%)

Latest News

Don't Forget Today's AbbVie Must-Own Date

The stock has gained 15% over the past year and we maintain the company is attractive to purchase for the secure payout.

Pure MHC To Partner With AbbVie On Oncology Research

Pure MHC To Partner With AbbVie On Oncology Research

Emergent Technologies, Inc. (ETI) announced today that its target discovery portfolio company, Pure MHC, and global biopharmaceutical company, AbbVie (NYSE:ABBV), will embark on a research and license agreement to discover...

AbbVie Announces Four New Global Research Collaborations Focused On Advancing Next-Generation Science

AbbVie Announces Four New Global Research Collaborations Focused On Advancing Next-Generation Science

- Collaborations will focus on key therapeutic areas, including oncology and immunology

Eight Weeks Of Treatment With AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen Of Glecaprevir/Pibrentasvir (G/P) For Chronic Hepatitis C Achieved High SVR[12] Rates In Genotype 1 Japanese Patients

Eight Weeks Of Treatment With AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen Of Glecaprevir/Pibrentasvir (G/P) For Chronic Hepatitis C Achieved High SVR[12] Rates In Genotype 1 Japanese Patients

- 99 percent (n=105/106) of genotype 1 (GT1) chronic HCV-infected Japanese patients without cirrhosis achieved SVR[12] with 8 weeks of G/P

Check These Dividend Dates

Must-own dates for some notable names.

Pfizer Unveils Positive Results from Study of Potential Humira Biosimilar

Pfizer Unveils Positive Results from Study of Potential Humira Biosimilar

Thursday's announcement marks Pfizer's third proposed biosimilar pipeline molecule to announce positive top-line results within the past four months.

Dividend Stock Picks Could Look Even Better in Coming Weeks

Dividend Stock Picks Could Look Even Better in Coming Weeks

Technical analysis shows investors interested in Boeing, Abbott Labs, Johnson & Johnson and Cardinal Health may increase returns by holding off on purchases.

Top 5 Dividend Stocks to Buy Now for 2017

Top 5 Dividend Stocks to Buy Now for 2017

Here is a look at some stocks that are poised for excellent dividend returns in 2017.

Top 10 Dividend Stocks You Need to Buy Now to Prepare for 2017

Top 10 Dividend Stocks You Need to Buy Now to Prepare for 2017

Here's a look at the 10 best dividend stocks to invest in for potential outperformance in 2017.

Analysts Mixed on Health Care Stocks in the New Year

Analysts Mixed on Health Care Stocks in the New Year

While there is deep uncertainty about how politics will affect the health care sector in the new year, analysts seem excited about some opportunities in pharmaceuticals.

AbbVie Submits New Drug Application To U.S. FDA For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C

AbbVie Submits New Drug Application To U.S. FDA For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C

- If approved, G/P will provide an eight week once-daily, ribavirin-free treatment option for HCV patients without cirrhosis across all major genotypes

Lockheed Takes Flak From Trump as Other Companies Brace for Fire

Lockheed Takes Flak From Trump as Other Companies Brace for Fire

The president-elect added Lockheed Martin to his long list of Twitter targets. So far the stock impact has been short-lived, but other potential targets are on the horizon

AbbVie Needs a Nudge to Get the Bull Going Again

AbbVie Needs a Nudge to Get the Bull Going Again

Overall, the next move for ABBV looks like it will be to the upside.

3 Hot and Undervalued Biotechs That Are Immune to Trump's Threats

3 Hot and Undervalued Biotechs That Are Immune to Trump's Threats

Another day, another industry damaged by the president-elect's rhetoric. But these three companies are strong enough to overcome arm-twisting over drug prices.

3 Portfolio Movers: AbbVie, Ford and GameStop

Two are up, one's down, let's see why.

Late-Breaking Ibrutinib (IMBRUVICA®) Data Show Complete Or Partial Response In Two-Thirds Of Patients With Chronic Graft-Versus-Host-Disease, A Frequent And Potentially Life-Threatening Complication Of Stem Cell Transplant

Late-Breaking Ibrutinib (IMBRUVICA®) Data Show Complete Or Partial Response In Two-Thirds Of Patients With Chronic Graft-Versus-Host-Disease, A Frequent And Potentially Life-Threatening Complication Of Stem Cell Transplant

- New Phase 2 data presented at the American Society of Hematology Annual Meeting highlight potential role of ibrutinib therapy beyond hematologic cancers

New Phase 2 Data Show Nearly Half Of Patients With Relapsed/Refractory Marginal Zone Lymphoma (MZL) Respond To Treatment With Ibrutinib (IMBRUVICA®)

New Phase 2 Data Show Nearly Half Of Patients With Relapsed/Refractory Marginal Zone Lymphoma (MZL) Respond To Treatment With Ibrutinib (IMBRUVICA®)

- Data presented at the American Society of Hematology Annual Meeting show 48% overall response rate

Favorable Response Rates Suggest Promise Of Ibrutinib (IMBRUVICA®) Combination Therapy In Two Common Types Of Non-Hodgkin's Lymphoma

Favorable Response Rates Suggest Promise Of Ibrutinib (IMBRUVICA®) Combination Therapy In Two Common Types Of Non-Hodgkin's Lymphoma

- New data available for ibrutinib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and in first-line follicular lymphoma (FL)

Crude Surge Marches Dow to Near Record Close

Crude Surge Marches Dow to Near Record Close

Wall Street was torn in two with the energy sector marching the Dow Jones Industrial Average higher, while health care and tech weighed on the Nasdaq.

Dow Climbs as Crude Rally Lights Fire Under Energy Sector, S&P 500 Falls

Dow Climbs as Crude Rally Lights Fire Under Energy Sector, S&P 500 Falls

The Dow Jones Industrial Average leads markets on Wednesday as a rally in crude oil lights a fire under the energy sector.

Stocks Mixed as Crude Rally Boosts Energy Shares

Stocks Mixed as Crude Rally Boosts Energy Shares

Stocks turn mixed Wednesday as a rally in crude oil fails to provide an across-the-board lift.

Healthcare Stocks Help Nasdaq Reach New Heights

Healthcare Stocks Help Nasdaq Reach New Heights

The Nasdaq rose 0.7% to an all-time high of 5,403. The S&P 500 was up 0.3%, and the Dow Jones Industrial Average gained 0.2%.